Table 1 Patient demographic and clinical data
From: Oral immunotherapy improves the quality of life of adults with food allergy
Parameter | Oral immunotherapy n = 44 | Controls n = 11 | p value |
|---|---|---|---|
Demographics and clinical background | |||
Gender (Male) | 26 (59.1%) | 4 (36.4%) | 0.2 |
Age (years) | 23.4 (20.4–26.6) | 19.8 (19.3- 25) | 0.2 |
Multiple food allergy | 15 (34.1%) | 6 (54.5%) | 0.3 |
Asthma | 26 (59.1%) | 7 (63.6%) | 1.0 |
HDM sensitization | 37 (84.1%) | 9 (81.8%) | 1.0 |
Prior anaphylaxis | 32 (72.7%) | 7 (63.6%) | 0.7 |
Prior use of epinephrine | 26 (59.1%) | 3 (27.3%) | 0.09 |
Oral immunotherapy | |||
Allergen treated | |||
Milk | 19 (43.2%) | ||
Egg | 2 (4.5%) | ||
Peanut | 9 (20.5%) | ||
Sesame | 6 (13.6%) | ||
Walnut | 3 (6.8%) | ||
Cashew | 3 (6.8%) | ||
Hazelnut | 2 (4.5%) | ||
Skin prick test (mm) | 9.0 (7.0–12.5) | ||
Starting dose (mg of protein) | 23.8 (10–90) | ||
Treatment duration (months) | 10.3 (6.3–16.0) | ||
Epinephrine | |||
In-clinic | 15 (34.1%) | ||
Home treatment | 10 (22.3%) | ||
Status | |||
Full desensitization | 33 (75%) | ||
Partial desensitization | 3 (6.8%) | ||
Failure | 8 (18.2%) | ||